U Protech, a Hangzhou-based biotech focused on next-generation protein degradation therapies, has raised tens of millions of renminbi in Angel and Angel+ financing rounds. The funding, led by Shanghai Biomedical Industry Equity Investment Fund’s transformation fund and Zheshang Venture Capital, will accelerate development of its PROTAC and molecular glue drug pipeline targeting autoimmune diseases and tumors.
Company Background
Founded in late 2021, U Protech specializes in proteolysis-targeting chimeras (PROTACs) and molecular glue drugs. Its pipeline aims to address unmet needs in autoimmune disorders and cancer, leveraging novel protein degradation mechanisms.
Funding Details
The proceeds will fund construction of an experimental lab, a customized compound screening library, pipeline optimization, and team expansion. The investment underscores growing interest in China’s emerging biotech sector, particularly in precision medicine.
Strategic Outlook
U Protech plans to advance its lead candidates into preclinical stages, with a focus on translating its protein degradation platform into clinical therapies. The partnership with Shanghai Biomedical and Zheshang Venture Capital provides critical capital and industry expertise to scale operations.-Fineline Info & Tech
